07:00 , Oct 15, 2012 |  BC Week In Review  |  Clinical News

GST P1-1 stroke assay diagnostic data

Proteome and researchers at the University of Geneva reported data from an analysis of blood levels of 29 proteins previously identified as early markers of brain damage associated with stroke showing that glutathione S-transferase P1-1...
08:00 , Nov 22, 2010 |  BC Week In Review  |  Company News

Epigenomics, Predictive Biosciences deal

Predictive Biosciences exercised a 2009 option to commercialize a prostate cancer test in the U.S. incorporating Epigenomics' glutathione S-transferase P1-1 (GST P1-1) DNA methylation biomarker. Epigenomics will receive an undisclosed license fee and is eligible...
07:00 , Oct 12, 2009 |  BC Week In Review  |  Clinical News

Telcyta: Updated Phase I/IIa data

Updated data from an open-label, U.S. Phase I/IIa trial in 100 evaluable patients showed that Telcyta maintenance therapy produced a median progression-free survival (PFS) and a median survival of 6.8 and 16.8 months, respectively, vs....
07:00 , Jun 8, 2009 |  BC Week In Review  |  Clinical News

Telcyta: Additional Phase III data

Additional data from the intent-to-treat (ITT) population of 125 patients in the open-label, international Phase III ASSIST-5 trial showed that Telcyta plus doxorubicin led to a median survival of 11.8 months compared with 7.8 months...
07:00 , May 4, 2009 |  BC Week In Review  |  Company News

Epigenomics, Predictive Biosciences deal

Predictive biosciences received a non-exclusive, U.S. license to develop and commercialize Epigenomics' glutathione S-transferase P1-1 ( GSTP1 ; GST P1-1 ) DNA methylation biomarker in molecular-based laboratory developed tests to diagnose prostate cancer. Further terms...
07:00 , Apr 16, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Sarcoma Microsomal glutathione S-transferase 1 (MGST1) In vitro studies suggest that MGST1 expression could help predict response to chemotherapy and guide...
08:00 , Nov 3, 2008 |  BC Week In Review  |  Clinical News

Telcyta: Phase III data

Data from the intent-to-treat (ITT) population of 125 patients with platinum-refractory or resistant ovarian cancer in the open-label, international Phase III ASSIST-5 trial, showed that Telcyta plus doxorubicin missed the co-primary endpoint of a significant...
07:00 , Oct 22, 2007 |  BC Week In Review  |  Clinical News

Telcyta: Phase III ongoing

FDA lifted a partial hold on the Phase III ASSIST-5 trial of Telcyta plus doxorubicin as second-line therapy for platinum-refractory or resistant ovarian cancer. TELK said it would perform an interim analysis of ASSIST-5 data...
01:55 , Oct 16, 2007 |  BC Extra  |  Clinical News

FDA lifts Telcyta hold

Telik (TELK) gained $0.48 (14%) to $3.94 on Monday after announcing that FDA lifted a partial hold on the Phase III ASSIST-5 trial of Telcyta ( TLK286 ) plus doxorubicin as second-line therapy for platinum-refractory...
07:00 , Jun 25, 2007 |  BC Week In Review  |  Clinical News

Telcyta: Phase III resumed

FDA converted the full clinical hold on Telcyta to a partial hold, which will allow TELK to continue to treat patients who are already enrolled in the Phase III ASSIST-3 and ASSIST-5 trials to treat...